Emerging Clinical Decision Support Tools

We are in an era of abundant technological innovation. Numerous emerging tools may allow clinicians to evaluate the status of cancer and make clinical decisions faster and less invasively. Failure to stay informed on the portfolio of emerging technologies risks delaying implementation of helpful new instruments. This session will review these clinical decision support tools

Target Audience

Upon completion of this activity, participants should be able to:

  • Identify key potential uses of saliva based clinical decision tools.
  • Identify key potential uses for plasma based clinical decision tools.
  • Identify key potential uses for AI based clinical decision tools.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.
Course opens: 
03/11/2024
Course expires: 
03/10/2026
Cost:
$0.00
Part of: 
2024 Multidisciplinary Head and Neck Cancers Symposium onDemand
Rating: 
0

Ben Kann, MD, is employed by Brigham and Women's Hospital and receives research funding from the NIH and RSNA.

Glenn Hanna, MD, is employed by Dana-Farber Cancer Insitute and receives research funding from Bicara and BMS. He is a consultant with Naveris and Regeneron and is on the advisory boards of Merck and Replimune.

Chamindie Punyadeera, PhD, is employed by Fragment Biotech and Griffith University and receives funding from MSD and has ownership interest in Fragment Biotech. She holds leadership positions with the Australian Academy of Technological Sciences, SAGE Athena and Women in Technology.

All relevant relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.